Roth Capital initiated coverage of Insmed (INSM) with a Buy rating and $212 price target The firm believes the company is well positioned for share upside in 2026. Brinsupri should continue to exceed Street expectations, the analyst tells investors in a research note. Roth assigns a 75% probability of success to Insmed’s Phase 3 ENCORE study, which it says could unlock $1.3B in frontline Arikayce revenue.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM:
- Insmed price target raised to $200 from $197 at RBC Capital
- Insmed: Strong Brensocatib Launch but Pipeline and Payer Uncertainties Keep Risk‑Reward Balanced at Hold
- Unusually active option classes on open January 9th
- Insmed: Strong Brinsupri Launch, Solid Arikayce Performance, and 2026 Catalysts Underpin Buy Rating
- Insmed Announces Strong 2025 Results and Pipeline Progress